- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471600
Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia (ENDOGLUcide)
February 26, 2013 updated by: University Hospital, Caen
Randomized Control Study : Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia
In several national anaesthesia societies, clear fluids are allowed up to 2 hours before general anaesthesia (GA) and light meals up to 6h.
Because of aspiration risk, strict fasting remains routine.
Recently, surgical studies proved that pre-operative carbohydrate-rich drink reduces preoperative discomfort without affecting gastric fluid volume and acidity.The aim of this study was to show the effects of preanaesthetic oral fluid in patients undergoing upper endoscopy without emergency.
The expected efficacy is a reduction of the preoperative discomfort.
The investigators thus propose a randomised prospective open-label study to assess efficacy of preanaesthetic oral glucose drink in patients undergoing upper endoscopy without emergency.
Study compare two groups : group "drink" (200 ml of fruit juice without pulp ± 200 ml of coffee or tea, 2 at 4 hours before the induction of anaesthesia) and group "overnight fasting".Discomfort was measured at 2 hours before GA (H-2), just before GA (H0) and 4h after anaesthesia (H+4).
Each item (anxiety, thirst, hunger, nervousness, tiredness, nausea) was estimated by visual analogue scale (VAS from 0 to 100mm) and handgrip strength by dynamometer.
Gastroenterologist assessed the quality of endoscopy (VAS), gastric residual fluid and acidity.The main aim of this study was to assess in patients referred for upper endoscopy under general anaesthesia, the effect of carbohydrate drink on preanaesthetic discomfort.
Secondary purpose were to compare quality of endoscopy, residual gastric volumes, gastric acidity and incidence of side effects.
118 patients will be included in the study.
A stratification will be made on the type of endoscopy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
119
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Caen, France, 14033
- University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age >= 18 yrs
- undergoing upper endoscopy procedure under general anesthesia without emergency
- informed written consent
Exclusion Criteria:
- emergency
- might impair gastrointestinal motility (intestinal obstruction, stenosis)
- diseases of the central and peripheral nervous system or neuromuscular diseases
- drug-induced gastric emptying disorders
- pregnancy
- ionic disorders (hyponatremia<125mmol/l ; hypokalemia<3,5mmol/l
- hemodynamic disorders (systolic arterial pressure <100mmHg)
- unstable diabetes (glycemia>2,5g/l) ± insulin- dependent diabetes ± diabetic gastroparesis
- the potential for difficult airway management
- understanding of the information
- patient with bad prognosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No intervention
Group overnight fasting
|
|
Active Comparator: Group drink
Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
|
group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percentage of preoperative patients increasing the anxiety score just before anaesthesia (H0)
Time Frame: at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
percentage of patients who increased the anxiety score (Visual Analogue Scale of Anxiety) just before anaesthesia.
|
at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
discomfort (anxiety, thirst, hunger, nervousness, nausea, tiredness) assessed by visual analogue scale (VAS) just before anaesthesia
Time Frame: at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
discomfort (anxiety, thirst, hunger, nervousness, nausea, tiredness) assessed by visual analogue scale (VAS from 0 to 100mmm) just before anaesthesia (at H0).
|
at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
handgrip strength assessed by dynamometer just before anaesthesia
Time Frame: at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
handgrip strength assessed by dynamometer just before anaesthesia
|
at H0 (just before anaesthesia). The participants will be followed for the duration of hospital stay, an expected average of one day.
|
quality of endoscopy estimated by gastroenterologist by visual analogue scale (VAS from 0 to 100mm)
Time Frame: The participants will be followed for the duration of hospital stay, an expected average of one day.
|
quality of endoscopy estimated by gastroenterologist by visual analogue scale (VAS from 0 to 100mm)
|
The participants will be followed for the duration of hospital stay, an expected average of one day.
|
gastric residual volume (ml)
Time Frame: The participants will be followed for the duration of hospital stay, an expected average of one day.
|
gastric residual volume (ml)
|
The participants will be followed for the duration of hospital stay, an expected average of one day.
|
amount of propofol (mg)
Time Frame: The participants will be followed for the duration of hospital stay, an expected average of one day.
|
the propofol consumption (mg)
|
The participants will be followed for the duration of hospital stay, an expected average of one day.
|
gastric acidity (pH)
Time Frame: The participants will be followed for the duration of hospital stay, an expected average of one day.
|
gastric acidity (pH) measured by pH indicator paper
|
The participants will be followed for the duration of hospital stay, an expected average of one day.
|
occurrence of vomiting
Time Frame: The participants will be followed for the duration of hospital stay, an expected average of one day.
|
occurrence of vomiting
|
The participants will be followed for the duration of hospital stay, an expected average of one day.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marie A PIQUET, PhD MD, CAEN, Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
October 18, 2011
First Submitted That Met QC Criteria
November 10, 2011
First Posted (Estimate)
November 15, 2011
Study Record Updates
Last Update Posted (Estimate)
February 27, 2013
Last Update Submitted That Met QC Criteria
February 26, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- 2008-A00255-50
- 08-009 (Caen, Hospital)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Gastrointestinal Endoscopy
-
Carol Davila University of Medicine and PharmacyNot yet recruitingUpper Gastrointestinal Endoscopy
-
Carol Davila University of Medicine and PharmacyNot yet recruitingUpper Gastrointestinal Endoscopy
-
Taipei Veterans General Hospital, TaiwanUnknownUpper Gastrointestinal EndoscopyTaiwan
-
Ain Shams UniversityCompletedUpper Gastrointestinal EndoscopyEgypt
-
Mahmoud Mohammed Osman AliAssiut UniversityCompletedUpper Gastrointestinal EndoscopyEgypt
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSedation in the Upper Gastrointestinal EndoscopyChina
-
Hospital Universiti Sains MalaysiaCompletedGastric Residual Volume | Upper EndoscopyMalaysia
-
Sohag UniversityCompletedAll Patients With Upper GIT Symptoms and Underwent Upper EndoscopyEgypt
-
Loma Linda UniversityRecruitingPoint of Care Ultrasound | Upper GI Bleeding | Gastric Content | Upper Endoscopy | GI BleedUnited States
-
Ethicon Endo-SurgeryCompletedSedation for Non-Emergent Upper and/or Lower EndoscopyUnited States
Clinical Trials on group drink
-
China Medical University HospitalRecruiting
-
National University of SingaporeRecruitingMild Cognitive ImpairmentSingapore
-
Charite University, Berlin, GermanyCompletedHealthy | AgedGermany
-
Abbott NutritionTerminatedRespiratory Infections in ChildrenUnited States
-
Chiayi Christian HospitalNot yet recruiting
-
Hospital General de MexicoFresenius KabiUnknownAcute Myeloid Leukemia, AdultMexico
-
Mingkwan Wongyingsinn, MDCompletedColorectal Neoplasms | Difficulty Walking | Bowel; Disease, Carbohydrate AbsorptionThailand
-
TCI Co., Ltd.Active, not recruiting